Evidence map›Paper›PMID 37674724›Full record

ArticleResearch square2023

Challenges associated with follow-up care after implementation of an HPV screen-and-treat program with ablative therapy for cervical cancer prevention in Iquitos, Peru: a mixed methods study.

Rachel Morse, Joanna Brown, E Jennifer Ríos López, Bryn A Prieto, Anna Kohler-Smith, Karina Gonzales Díaz, Magaly Figueredo Escudero, Daniel Lenin Del Cuadro, Giannina Vásquez Del Aguila, Henrry Daza Grandez and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Rachel MorseDepartment of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine.
Joanna BrownAsociación Bené ca PRISMA.
E Jennifer Ríos LópezAsociación Bené ca PRISMA.
Bryn A PrietoDepartment of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine.
Anna Kohler-SmithAsociación Bené ca PRISMA.
Karina Gonzales DíazDepartment of Cancer Control and Prevention, Gerencia Regional de Salud de Loreto.
Magaly Figueredo EscuderoDepartment of Cancer Control and Prevention, Gerencia Regional de Salud de Loreto.
Daniel Lenin Del CuadroDepartment of Cancer Control and Prevention, Gerencia Regional de Salud de Loreto.
Giannina Vásquez Del AguilaDepartment of Cancer Control and Prevention, Gerencia Regional de Salud de Loreto.
Henrry Daza GrandezO cina de Servicios de Salud, Gerencia Regional de Salud.
Graciela MezaFacultad de Medicina Humana, Universidad Nacional de la Amazonía Peruana.
J Kathleen TracyDepartment of Medicine, University of Vermont College of Medicine.
Patti E GravittDepartment of Epidemiology and Public Health, University of Maryland School of Medicine.
Valerie A Paz-SoldanDepartment of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine.
Proyecto Precancer Study Group
University of Vermont · USDirección Regional de Salud del Callao · PEProteogenomics Research Institute for Systems Medicine · USUniversidad Nacional de la Amazonía Peruana · PE

Funding

Translating Molecular Diagnostics for Cervical Cancer Prevention into PracticeR01CA190366 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI PAZ-SOLDAN, VALERIE ANDREA, TRACY, J. KATHLEEN · 2016 to 2020
$2.7M
Translating Molecular Diagnostics for Cervical Cancer Prevention into PracticeU01CA190366 · NCI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI PAZ-SOLDAN, VALERIE ANDREA, TRACY, J. KATHLEEN · 2021 to 2025
$2.1M
NCI NIH HHS R01 CA190366NCI NIH HHS U01 CA190366
6 · The paper itself

Abstract

Background: Cervical cancer is a preventable cancer; however, decreasing its prevalence requires early detection and treatment strategies that reduce rates of loss to follow-up. This study explores factors associated with loss to follow-up among HPV-positive women after implementation of a screen-and-treat approach with visual triage and ablative therapy for cervical cancer prevention in Iquitos, Peru. Methods: We conducted semi-structured interviews with nurse-midwives (n = 15) working in cervical cancer prevention and women (n = 24) who were recorded as lost to follow-up after positive HPV results. We used the Health Care Access Barriers Model to guide analysis. We utilize manifest content analysis to describe barriers to follow-up according to the nurse-midwives and thematic analysis to report themes from the women's perspectives. We also report the steps and time taken to contact women and report discrepancies and concordances between nurse-midwives and women regarding reasons for loss to follow-up. Results: Women in this study expressed a desire to receive treatment. Barriers, including fragmented and incomplete registry systems, made receiving follow-up care more challenging. Nurse-midwives faced structural barriers in attempting to deliver positive results to women who were challenging to contact, and women did not have clear knowledge of how to receive their HPV results. Women faced cognitive barriers including a lack of understanding about HPV results and treatment procedures, fear or anxiety about HPV or treatment, and confusion about the follow-up process. Women also reported having important work matters as a barrier. Reported financial barriers were minimal. There was agreement between women's and nurse-midwives' reported barriers to follow-up in slightly over half of the cases. Conclusion: This study highlights the barriers to follow-up after implementation of a primary-level HPV-based screen-and-treat approach. While some barriers that have previously been associated with loss to follow-up were not observed in this study (e.g., financial), we emphasize the need for screen-and-treat programs to focus on strategies that can address incomplete registry systems, structural challenges in results delivery, cognitive barriers in understanding results and treatment, and work-related barriers.

Indexed as

Cervical CancerHPV ScreeningLost to follow-upScreen-and-treat

Identifiers

PMID37674724
PMCPMC10479451
OpenAlexW4386086034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.